Cladribine as treatment of multiple sclerosis, real world experience
BestPractice | Sept 2019 | | ECTRIMS 2019
In this MEDtalk Elisabeth Gulowsen Celius present data from a real-world population of patients with previous treatments cladribine. Cladribine is a synthetic purine nucleoside analogue administered orally as two five day treatment cycles week 1 and 5 and repeated one year later. Cladribine gained market access in Norway in May 2018.